Literature DB >> 6872349

Serum IgA1 and IgA2 in normal adults and patients with systemic lupus erythematosus and hepatic disease.

M E Conley, W J Koopman.   

Abstract

As an early step in examining the factors that regulate synthesis of the IgA subclasses, IgA1 and IgA2, we determined the serum levels of IgA1, IgA2 and total IgA in 50 normal adults, 20 patients with systemic lupus erythematosus (SLE), and 11 patients with liver disease. A quantitative solid phase radioimmunoassay using subclass specific monoclonal hybridoma antibodies was used. Within the normal population there were large variations in the concentrations of IgA1 and IgA2. The levels of IgA1 and IgA2 in samples from males were not significantly different from those from females. However, the mean concentration of IgA1 in samples from Blacks was significantly lower than that from Caucasians, P less than 0.005. In the control population IgA2 constituted from 6 to 35% of the total serum IgA and the levels of IgA1 did not correlate with the levels of IgA2. The mean IgA1 and total IgA in samples obtained from patients with SLE were significantly higher than those from the normal population (P less than 0.0001) although there was no significant difference in the levels of IgA2 in the two groups. In the samples obtained from patients with liver disease both IgA1 and IgA2 were markedly elevated and the levels of IgA1 did correlate with the levels of IgA2. These results indicate that the serum levels of IgA1 and IgA2 are controlled by factors that influence each subclass independently as well as factors that affect each subclass equivalently.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872349     DOI: 10.1016/0090-1229(83)90123-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosus.

Authors:  N Pourmand; M Wahren-Herlenius; I Gunnarsson; E Svenungsson; B Löfström; Y Ioannou; D A Isenberg; C G Magnusson
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

Authors:  M E Conley; A Lavoie; C Briggs; P Brown; C Guerra; J M Puck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  R Coppo; B Basolo; G Piccoli; G Mazzucco; M R Bulzomì; D Roccatello; M De Marchi; A O Carbonara; G Barbiano di Belgiojoso
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

4.  IgA subclass antibodies to gliadin in serum and intestinal juice of patients with coeliac disease.

Authors:  U Volta; N Molinaro; D Fratangelo; F B Bianchi
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

5.  Kinetics of anti-Campylobacter jejuni monomeric and polymeric immunoglobulin A1 and A2 responses in serum during acute enteritis.

Authors:  F O Mascart-Lemone; J R Duchateau; J Oosterom; J P Butzler; D L Delacroix
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

6.  Light-chain ratio of serum IgA1 in IgA nephropathy.

Authors:  S H Chui; C W Lam; W H Lewis; K N Lai
Journal:  J Clin Immunol       Date:  1991-07       Impact factor: 8.317

7.  Lack of IgA subclass restriction in antibody response to phosphorylcholine, beta lactoglobulin and tetanus toxoid.

Authors:  M E Conley; D E Briles
Journal:  Immunology       Date:  1984-11       Impact factor: 7.397

8.  [The gastrointestinal tract as an immunologic organ: the gut-associated immune system].

Authors:  G Börsch
Journal:  Klin Wochenschr       Date:  1984-08-01

9.  Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation.

Authors:  Hyemee Joo; Christine Coquery; Yaming Xue; Ingrid Gayet; Stacey R Dillon; Marilynn Punaro; Gerard Zurawski; Jacques Banchereau; Virginia Pascual; Sangkon Oh
Journal:  J Exp Med       Date:  2012-06-11       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.